Appeal No. 2002-2279 Page 3
Application No. 08/556,667
Reynolds et al. (Reynolds), “Model System for Removing Neuroblastoma Cells from
Bone Marrow Using Monoclonal Antibodies and Magnetic Immunobeads,” Cancer
Research, Vol. 46, pp. 5882-5886 (November 1986)
Kessler et al. (Kessler), “Large-Scale Purification and Characterization of CD34-Positive
Hematopoietic Progenitor Cells,” Blood, Vol. 70 (Suppl. 1), Abstract No. 321a (1987)
Patel et al. (Patel), “Use of Density Perturbation to Isolate Immunologically Distinct
Populations of Cells,” Journal of Immunological Methods, Vol. 163, pp. 241-251 (1993)
The claims stand rejected as follows:
I. Claims 4, 5, 8, 9, 11-14, 18, 19 and 28 under 35 U.S.C. § 103 as unpatentable over
Grenier and Reynolds.
II. Claims 4, 5, 8, 9, 11-14, 18, 19 and 28 under 35 U.S.C. § 103 as unpatentable over
Pry and Reynolds.
III. Claims 6, 7 and 9 under 35 U.S.C. § 103 as unpatentable over Grenier, Pry,
Reynolds and Kessler.
IV. Claim 15 under 35 U.S.C. § 103 as unpatentable over Grenier, Pry, Reynolds and
Giaever.
V. Claims 16 and 17 under 35 U.S.C. § 103 as unpatentable over Grenier, Pry,
Reynolds and Patel.
VI. Claims 10 and 20 under 35 U.S.C. § 103 as unpatentable over Grenier, Pry,
Reynolds, Kessler and Falkenburg.
BACKGROUND
“The enhancement of a population or a subpopulation of a sample such as
hematopoietic stem cells (HSC) can be utilized for many types of applications . . . In
addition to enhancement . . . , it is often necessary to remove undesired populations or
subpopulations. For example, . . . [i]f the bone marrow is to be purged of [non-
Hodgkin’s B lymphoma cells] and reinfused into the patient, it is important that the bone
marrow be completely purged and that the bone marrow be not otherwise damaged”
(specification, pages 1 and 2).
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: November 3, 2007